Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal

BASF Licensing Precise Crispr Editing from Broad Institute

Crispr-Cas9 illustration

The global chemical company BASF is licensing a more precise form of genome editing from the Broad Institute, a genetics research center affiliated with Harvard University and MIT. . . . → Read More: BASF Licensing Precise Crispr Editing from Broad Institute

Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Human lungs illustration

A company in Maryland developing alternatives to human organ transplants is licensing a technology to help create 3-D printed lungs for transplantation with bioinks derived from tobacco plants. . . . → Read More: Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Handshake

Drug maker AbbVie and biotechnology company Morphic Therapeutic are collaborating on new treatments for fibrosis based on Morphic’s technology blocking proteins that promote fibrosis. . . . → Read More: Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Model Biotech Materials Sharing Agreement Unveiled

Lab jars and beakers

A document with standard legal language for terms and conditions of sharing biotechnology materials is now available for academic and industry research labs. . . . → Read More: Model Biotech Materials Sharing Agreement Unveiled

Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

T-cells illustration

A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

Biotech in $3.7B Licensing Deal for Hepatitis-B

Hepatitis-B virus

A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B

Patents Awarded for Stem Cell Heart Disease Technologies

U.S. Patent and Trademark Office

A company developing treatments for heart disease using stem cells to regenerate healthy heart tissue received two new patents for techniques supporting its core processes. . . . → Read More: Patents Awarded for Stem Cell Heart Disease Technologies

Gilead Gains Genome-Editing Hepatitis B Therapy

Hepatitis-B virus

Biopharmaceutical company Gilead Sciences is acquiring a genome-editing technology for treating hepatitis-B, a viral disease affecting the liver. . . . → Read More: Gilead Gains Genome-Editing Hepatitis B Therapy

Appeals Court Backs Broad Institute in Crispr Case

Crispr genome edits illustration

A U.S. appeals court supported the Broad Institute’s claims it invented a separate Crispr technology from University of California, affirming a previous U.S. patent office ruling. . . . → Read More: Appeals Court Backs Broad Institute in Crispr Case